Biodexa Pharmaceuticals Announces The Publication Of The Results Of Phase I Study PNOC015 Of MTX110 In The Treatment Of Pediatric Patients With DMG In The Journal Of Neuro-Oncology
Portfolio Pulse from Benzinga Newsdesk
Biodexa Pharmaceuticals has published the results of its Phase I study PNOC015 of MTX110 in the treatment of pediatric patients with DMG. The study demonstrated an acceptable safety profile and encouraging efficacy, with a median overall survival of 26.1 months, compared to historical data of 10.0 months.
July 06, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The positive results from Biodexa Pharmaceuticals' Phase I study of MTX110 could potentially boost the company's stock in the short term.
The successful results of the Phase I study of MTX110 indicate that the drug is effective and safe for use in pediatric patients with DMG. This could potentially lead to increased demand for the drug, which would positively impact Biodexa Pharmaceuticals' revenues and, consequently, its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100